Response to Comments: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells

This document is a response-to-comments notice for MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells (LCD DL38643). It records the comment period (05/28/2020–07/12/2020), notice period start (05/20/2021), the LCD effective date (07/04/2021), and a title revision; no clinical coverage criteria are provided in this document. For substantive coverage rules, refer to LCD DL38643 itself rather than this response-to-comments notice.